Detalhe da pesquisa
1.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437622
2.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood
; 139(7): 1026-1038, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496014
3.
Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
Dermatol Ther
; 35(7): e15538, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477952
4.
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Cancer Immunol Immunother
; 70(3): 869-874, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857184
5.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med
; 377(26): 2545-2554, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226764
6.
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Oncologist
; 24(7): 955-962, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568021
7.
A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
Kidney Int
; 94(1): 199-205, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29759418
8.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica
; 103(5): 874-879, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419429
9.
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Cytotherapy
; 20(12): 1415-1418, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30385043
10.
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Cancer
; 123(8): 1363-1371, 2017 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27984652
11.
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
Am J Hematol
; 92(9): 879-884, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28512788
12.
Making Progress in PTCL: Significant Unmet Needs.
Oncology (Williston Park)
; 36(5): 296, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576177
13.
Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.
Am J Hematol
; 91(7): 672-6, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27012928
14.
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
N Engl J Med
; 367(2): 135-45, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22784116
15.
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Cancer
; 120(2): 222-8, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122387
16.
'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.
Br J Haematol
; 166(3): 369-74, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24761809
17.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
J Hematol Oncol
; 17(1): 19, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644469
18.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Transplant Cell Ther
; 2024 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494076
19.
Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol.
Blood Adv
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38625984
20.
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Blood Adv
; 8(3): 653-666, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38113468